CDKN2A and astrocytoma (excluding glioblastoma): Worse survival in patients with astrocytoma and <i>CDKN2A/B</i> hemizygous loss was observed, specifically in WHO grade 2, but this prognostic effect disappeared when adjusting for clinical factors.